Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|October 15, 2024
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myelomaMeletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple MyelomaHans C Lee, Naresh Bumma, Joshua Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I StudyErlene K Seymour, Husain Yar Khan, Yiwei Li, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
Leukemia & Lymphoma|March 28, 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaRuben Niesvizky, Ashraf Z Badros, Luciano J Costa, et al.
The Lancet. Oncology|January 15, 2023
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trialDominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
JCO Oncology Practice|May 30, 2020
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United StatesYang Yu, Niquelle Brown Wade, Amie E Hwang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Pageof 6